GlassScriptPhysician profile
Brooke Ashley Johnson
NPI 1871187674
$1,324.71
in general payments reported to CMS, 2019-2025
19 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $62.58 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.91 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $228.58 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $172.39 | 2025 | |
| Exact Sciences Corporation | $84.83 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $80.20 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $70.85 | 2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $54.54 | 2024-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.18 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $42.26 | 2025 | Trelegy Ellipta |
| Lundbeck LLC | $35.98 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $34.72 | 2025 | Capvaxive, Gardasil 9 |
| Amgen INC. | $34.60 | 2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $33.56 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.30 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $17.90 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $17.71 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $17.67 | 2025 | Austedo Xr |
| Dexcom, INC. | $17.25 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $14.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.